Locteron Showing Promise for Hepatitis C
Share
Follow Us
OctoPlus says hepatitis C drug effective in study
Tue Nov 6, 2007
AMSTERDAM (Reuters) – Dutch biotechnology firm OctoPlus said on Tuesday European safety and efficacy Phase IIa studies have shown an antiviral effect for its chronic hepatitis C drug Locteron.
“A statistically significant dose response was observed in the study,” the company said in a statement, adding that the drug was tolerated at all doses.
The company, which has four other products in pre-clinical and clinical development, said approximately 90 percent of adverse events were rated as mild.
OctoPlus is co-developing Locteron with its partner Biolex Therapeutics, which plans to commence a European safety and efficacy Phase IIb trial of the drug in mid-2008.
With Locteron, OctoPlus is aiming to develop a treatment for patients with chronic hepatitis C, with fewer side effects and a more convenient dosing schedule compared with current therapies.
(Reporting by Harro ten Wolde)
